ifosfamide has been researched along with Carcinoma in 71 studies
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 9.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| "The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection." | 9.10 | Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. ( Blumenschein, G; Clayman, G; Diaz, EM; Garden, AS; Gillenwater, A; Ginsberg, LE; Glisson, BS; Goepfert, H; Hong, WK; Kies, MS; Lippman, SM; Liu, DD; Morrison, WH; Papadimitrakopoulou, VA; Schommer, D, 2003) |
| "A phase I or II trial was conducted to assess the toxicity and the efficacy of a tandem high dose chemotherapy combining ifosfamide, carboplatin, and teniposide in patients with poor prognosis ovarian carcinoma." | 9.08 | Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. ( André, T; Bouleuc, C; Hannoun, L; Houry, S; Izrael, V; Lefranc, JP; Lotz, JP; Macovei, C; Touboul, E; Uzan, S, 1996) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of cisplatin (CDDP) and ifosfamide (IFX) as neoadjuvant chemotherapy in advanced cervical carcinoma (ACC)." | 9.08 | Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. ( Arroyo, A; Castaldi, J; Cuevas, MA; Ferreyra, R; Focaccia, G; Lacava, J; Leone, B; Machiavelli, M; Perez, J; Rabinovich, M; Romero, A; Suttora, G; Vallejo, C, 1996) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 9.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix." | 9.07 | Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993) |
| "Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)." | 9.07 | Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994) |
| "Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy." | 9.06 | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 7.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "Thirty patients aged 34-69 years (median 56) with previously untreated FIGO Stage III and IV ovarian carcinoma were given carboplatin (400 mg/m2) and ifosfamide (5 g/m2) with mesna every 28 days for a median of 3 cycles, followed, where possible, by laparotomy." | 7.68 | Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. ( Green, JA; Lim, JT, 1993) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 7.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 7.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 7.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s." | 6.38 | Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993) |
| "Etoposide (100 mg/m2) was given i." | 5.28 | A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. ( Kaern, J; Tropé, C; Vergote, I; Vossli, S, 1990) |
| "To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5-fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) PATIENTS AND METHODS: Between October 1998 and August 2001, 35 Chinese patients with stage IVb NPC (N3a:12, N3b:23) were treated with by concurrent chemoirradiation using cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with 1." | 5.11 | A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma. ( Au, GK; Chua, DT; Sham, JS, 2004) |
| " Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma." | 5.10 | Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience. ( Bakshi, AV; Deshmukh, CD; Mazumdar, AT; Mistry, RC; Pai, VR; Parikh, DM; Parikh, PM; Pathak, KA, 2003) |
| "The objectives of this study were to determine the efficacy, organ-preservation rate, and safety of intraarterial (IA) cisplatin in combination with intravenous paclitaxel and ifosfamide in patients with locally advanced carcinoma of the paranasal sinuses who required orbital exenteration or major craniofacial resection for complete tumor resection." | 5.10 | Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. ( Blumenschein, G; Clayman, G; Diaz, EM; Garden, AS; Gillenwater, A; Ginsberg, LE; Glisson, BS; Goepfert, H; Hong, WK; Kies, MS; Lippman, SM; Liu, DD; Morrison, WH; Papadimitrakopoulou, VA; Schommer, D, 2003) |
| "A phase I or II trial was conducted to assess the toxicity and the efficacy of a tandem high dose chemotherapy combining ifosfamide, carboplatin, and teniposide in patients with poor prognosis ovarian carcinoma." | 5.08 | Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. ( André, T; Bouleuc, C; Hannoun, L; Houry, S; Izrael, V; Lefranc, JP; Lotz, JP; Macovei, C; Touboul, E; Uzan, S, 1996) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of cisplatin (CDDP) and ifosfamide (IFX) as neoadjuvant chemotherapy in advanced cervical carcinoma (ACC)." | 5.08 | Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma. ( Arroyo, A; Castaldi, J; Cuevas, MA; Ferreyra, R; Focaccia, G; Lacava, J; Leone, B; Machiavelli, M; Perez, J; Rabinovich, M; Romero, A; Suttora, G; Vallejo, C, 1996) |
| "We have reported the results of a previous Phase II trial of two courses of neoadjuvant mitomycin (6 mg/m2), ifosfamide (3 g/m2) and cisplatin (50 mg/m2) (MIC) in squamous or anaplastic carcinoma of the oesophagus." | 5.08 | A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus. ( Cullen, MH; Darnton, SJ; Matthews, HR; McAleer, JA; McManus, KG; Steyn, RS, 1998) |
| "A phase II trial of ifosfamide (IFX) and mesna was conducted by the GOG in patients with recurrent or advanced nonsquamous carcinoma of the cervix." | 5.07 | Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study. ( Blessing, JA; DiSaia, PJ; McGuire, WP; Sutton, GP, 1993) |
| "A phase II trial was performed to evaluate the efficacy and toxicity of a combination of ifosfamide (IFX) and mitoxantrone (MXN) as first-line chemotherapy for metastatic breast carcinoma." | 5.07 | Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer. ( Bianco, A; Cuevas, MA; Lacava, JA; Leone, BA; Machiavelli, M; Perez, JE; Rabinovich, MG; Rodriguez, R; Romero, A; Vallejo, CT, 1993) |
| "Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide." | 5.07 | Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. ( Barón, FJ; Buesa, JM; Esteban, E; Estrada, E; Fernández, R; Gracia, M; Lacave, AJ; Palacio, I, 1991) |
| "Phase II trial in metastatic urothelial carcinoma using a novel combination chemotherapy regimen consisting of vinblastine, ifosfamide, and gallium nitrate (VIG)." | 5.07 | Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. ( Ansari, R; Dreicer, R; Einhorn, LH; Gonin, R; Loehrer, PJ; Roth, BJ, 1994) |
| "Ifosfamide (isophosphamide) and mesna (2-mercaptoethane sodium sulfonate) were administered intravenously at monthly intervals to 46 patients with advanced epithelial ovarian carcinoma refractory to or recurrent after cisplatin-containing combination chemotherapy." | 5.06 | Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. ( Berman, ML; Blessing, JA; Homesley, HD; Malfetano, J; Sutton, GP, 1989) |
| "To evaluate the efficacy and safety of gemcitabine combined with ifosfamide (GI regimen)in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy." | 3.81 | [Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy]. ( Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S, 2015) |
| "Thirty patients aged 34-69 years (median 56) with previously untreated FIGO Stage III and IV ovarian carcinoma were given carboplatin (400 mg/m2) and ifosfamide (5 g/m2) with mesna every 28 days for a median of 3 cycles, followed, where possible, by laparotomy." | 3.68 | Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. ( Green, JA; Lim, JT, 1993) |
| "A Phase II study of VP-16 (etoposide), ifosfamide/mesna, and cisplatin (VIP) in advanced and recurrent carcinoma of the cervix was initiated March 1989." | 3.68 | Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. ( Kredentser, DC, 1991) |
| "The Gastrointestinal Tumor Study Group (GITSG) investigated the efficacy of ifosfamide with mesna uroprotection in 30 patients with advanced inoperable pancreatic carcinoma that was confirmed histologically." | 3.67 | Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. ( , 1989) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 3.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "Twenty-one chemotherapy naive ovarian cancer patients with stage III and minimal residual tumor were treated with cisplatin 75 mg/m2 and mitoxantrone 15 mg/m2 (1st day) by intraperitoneal (i." | 2.69 | Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. ( Aydmer, A; Bengisu, E; Berkman, S; Saip, P; Salihoğlu, Y; Topuz, E, 1998) |
| "Etoposide was given at 150 mg/m2 every 12 h for six doses on days 1-3." | 2.69 | High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. ( Aleman, A; Anderlini, P; Bast, RC; Bevers, M; Bodurka-Bevers, D; Boyer, J; Burke, T; Champlin, RE; Donato, ML; Freedman, R; Gajewski, JG; Gershenson, D; Giralt, S; Ippoliti, C; Korbling, M; Lauppe, J; Levenback, C; Molldrem, J; Ueno, N; Wharton, JT; Wolf, J, 2000) |
| "Radiation-induced osteosarcomas are a recognized complication of radiation therapy." | 2.53 | Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature. ( Benjaafar, N; Echchikhi, Y; Kebdani, T; Loughlimi, H; Touil, A, 2016) |
| "Intraperitoneal carcinomatosis (PC) may occur with several tumor entities." | 2.49 | Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. ( Binder, S; Keese, M; Lewis, AL; Löhr, JM, 2013) |
| "In advanced epithelial ovarian cancer, it has been tested in association with cisplatin, achieving results equal, if not better than cyclophosphamide, with acceptable toxicity." | 2.42 | Ifosfamide in the treatment of malignant epithelial ovarian tumors. ( Fei, F; Fruscio, R; Lissoni, AA; Rossi, R; Villa, A; Zani, G, 2003) |
| "Thymomas and thymic carcinomas are unique tumors of the anterior mediastinum." | 2.41 | Thymic malignancies. ( Loehrer, PJ; Wick, MR, 2001) |
| " Such simultaneous administration enabled us to substantially increase the dosage intensity of both, thereby increasing the effectiveness of each drug." | 2.40 | Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. ( Lackman, RD; Weiss, AJ, 1997) |
| "In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses." | 2.38 | Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992) |
| "Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s." | 2.38 | Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993) |
| "NUT carcinoma is an extremely rare disease and yet extremely aggressive with 2-year survival of only approximately 19% and median survival of 6 to 9 months." | 1.56 | Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation. ( Chang, JS; Pan, M, 2020) |
| "treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1 expressing cells." | 1.34 | Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. ( Löhr, M; Samel, S, 2007) |
| "A total of 25 patients with epithelial ovarian cancer were treated with second-line carboplatin, etoposide, and ifosfamide (ICE) following failure of first-line cisplatin-based combination chemotherapy." | 1.29 | Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer. ( Fanning, J; Hilgers, RD; Hutson, E, 1994) |
| "These were neuroepithelioma, lymphoma, desmoplastic small-cell tumor, melanoma, and clear-cell sarcoma." | 1.29 | Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site. ( Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E, 1995) |
| "Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990) |
| "Etoposide (100 mg/m2) was given i." | 1.28 | A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. ( Kaern, J; Tropé, C; Vergote, I; Vossli, S, 1990) |
| "A 62-year-old woman developed subacute renal failure after the repeated administration of ifosfamide (IFX), despite its combination with continuous sodium 2-mercaptoethane sulfonate (mesna) infusion." | 1.28 | Severe renal failure following high-dose ifosfamide and mesna. ( de Jong, PE; Elema, JD; Mulder, NH; Willemse, PH, 1989) |
| "Ifosfamide/mesna has activity in a wide range of gynecologic malignancies." | 1.28 | Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (15.49) | 18.7374 |
| 1990's | 35 (49.30) | 18.2507 |
| 2000's | 14 (19.72) | 29.6817 |
| 2010's | 7 (9.86) | 24.3611 |
| 2020's | 4 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Muramatsu, J | 1 |
| Takada, K | 1 |
| Sugita, S | 1 |
| Tsuchiya, T | 1 |
| Yamamoto, K | 1 |
| Takagi, M | 1 |
| Murase, K | 1 |
| Ameda, S | 1 |
| Arihara, Y | 1 |
| Miyanishi, K | 1 |
| Sakata, KI | 1 |
| Kato, J | 1 |
| Lemelle, L | 1 |
| Flaadt, T | 1 |
| Fresneau, B | 1 |
| Moya-Plana, A | 1 |
| Timmermann, B | 1 |
| Roganovic, J | 1 |
| Ferrari, A | 1 |
| Fichera, G | 1 |
| Lauer, UM | 1 |
| Ben-Ami, T | 1 |
| Schneider, DT | 1 |
| Vokuhl, C | 1 |
| Bolle, S | 1 |
| Fox, E | 1 |
| DuBois, SG | 1 |
| Rodriguez-Galindo, C | 1 |
| Bisogno, G | 1 |
| Surun, A | 1 |
| Brecht, IB | 1 |
| Orbach, D | 1 |
| Sánchez-Romero, C | 1 |
| Paes de Almeida, O | 1 |
| Díaz Molina, JP | 1 |
| Carlos, R | 1 |
| Pan, M | 1 |
| Chang, JS | 1 |
| Binder, S | 1 |
| Lewis, AL | 1 |
| Löhr, JM | 1 |
| Keese, M | 1 |
| Schneider, C | 1 |
| Kamaly-Asl, I | 1 |
| Ramaswamy, V | 1 |
| Lafay-Cousin, L | 1 |
| Kulkarni, AV | 1 |
| Rutka, JT | 1 |
| Remke, M | 1 |
| Coluccia, D | 1 |
| Tabori, U | 1 |
| Hawkins, C | 1 |
| Bouffet, E | 1 |
| Taylor, MD | 1 |
| Vulsteke, C | 1 |
| Lurquin, E | 1 |
| Debiec-Rychter, M | 1 |
| Gheysens, O | 1 |
| Nuyts, S | 1 |
| Schoenaers, J | 1 |
| Politis, C | 1 |
| Mebis, J | 1 |
| Hauben, E | 1 |
| Clement, PM | 1 |
| Hu, S | 1 |
| He, X | 1 |
| Dong, M | 1 |
| Jia, B | 1 |
| Zhou, S | 1 |
| Yang, J | 1 |
| Yang, S | 1 |
| Zhang, C | 1 |
| Liu, P | 1 |
| Qin, Y | 1 |
| Gui, L | 1 |
| Matsuo, K | 1 |
| Takazawa, Y | 1 |
| Ross, MS | 1 |
| Elishaev, E | 1 |
| Podzielinski, I | 1 |
| Yunokawa, M | 1 |
| Sheridan, TB | 1 |
| Bush, SH | 1 |
| Klobocista, MM | 1 |
| Blake, EA | 1 |
| Takano, T | 1 |
| Matsuzaki, S | 1 |
| Baba, T | 1 |
| Satoh, S | 1 |
| Shida, M | 1 |
| Nishikawa, T | 1 |
| Ikeda, Y | 1 |
| Adachi, S | 1 |
| Yokoyama, T | 1 |
| Takekuma, M | 1 |
| Fujiwara, K | 2 |
| Hazama, Y | 1 |
| Kadogami, D | 1 |
| Moffitt, MN | 1 |
| Takeuchi, S | 1 |
| Nishimura, M | 1 |
| Iwasaki, K | 1 |
| Ushioda, N | 1 |
| Johnson, MS | 1 |
| Yoshida, M | 1 |
| Hakam, A | 1 |
| Li, SW | 1 |
| Richmond, AM | 1 |
| Machida, H | 1 |
| Mhawech-Fauceglia, P | 1 |
| Ueda, Y | 1 |
| Yoshino, K | 1 |
| Yamaguchi, K | 1 |
| Oishi, T | 1 |
| Kajiwara, H | 1 |
| Hasegawa, K | 1 |
| Yasuda, M | 1 |
| Kawana, K | 1 |
| Suda, K | 1 |
| Miyake, TM | 1 |
| Moriya, T | 1 |
| Yuba, Y | 1 |
| Morgan, T | 1 |
| Fukagawa, T | 1 |
| Wakatsuki, A | 1 |
| Sugiyama, T | 1 |
| Pejovic, T | 1 |
| Nagano, T | 1 |
| Shimoya, K | 1 |
| Andoh, M | 1 |
| Shiki, Y | 1 |
| Enomoto, T | 1 |
| Sasaki, T | 1 |
| Mikami, M | 1 |
| Shimada, M | 1 |
| Konishi, I | 1 |
| Kimura, T | 1 |
| Post, MD | 1 |
| Shahzad, MM | 1 |
| Im, DD | 1 |
| Yoshida, H | 1 |
| Omatsu, K | 1 |
| Ueland, FR | 1 |
| Kelley, JL | 1 |
| Karabakhtsian, RG | 1 |
| Roman, LD | 1 |
| Echchikhi, Y | 1 |
| Loughlimi, H | 1 |
| Touil, A | 1 |
| Kebdani, T | 1 |
| Benjaafar, N | 1 |
| Lin, HH | 1 |
| Lin, JN | 1 |
| Grushka, JR | 1 |
| Ryckman, J | 1 |
| Mueller, C | 1 |
| Roessingh, Ade B | 1 |
| Walton, JM | 1 |
| St Vil, D | 1 |
| Laberge, JM | 1 |
| Bernard, C | 1 |
| Nguyen, VH | 1 |
| Puligandla, PS | 1 |
| Burnside, N | 1 |
| MacGowan, SW | 1 |
| Misiura, K | 1 |
| Szymanowicz, D | 1 |
| Kuśnierczyk, H | 1 |
| Wietrzyk, J | 1 |
| Opolski, A | 1 |
| Pai, VR | 1 |
| Mazumdar, AT | 1 |
| Deshmukh, CD | 1 |
| Bakshi, AV | 1 |
| Parikh, DM | 1 |
| Parikh, PM | 1 |
| Mistry, RC | 1 |
| Pathak, KA | 1 |
| Lissoni, AA | 1 |
| Fei, F | 1 |
| Rossi, R | 1 |
| Fruscio, R | 1 |
| Villa, A | 1 |
| Zani, G | 1 |
| Papadimitrakopoulou, VA | 1 |
| Ginsberg, LE | 1 |
| Garden, AS | 1 |
| Kies, MS | 1 |
| Glisson, BS | 1 |
| Diaz, EM | 1 |
| Clayman, G | 1 |
| Morrison, WH | 1 |
| Liu, DD | 1 |
| Blumenschein, G | 1 |
| Lippman, SM | 1 |
| Schommer, D | 1 |
| Gillenwater, A | 1 |
| Goepfert, H | 1 |
| Hong, WK | 1 |
| Chua, DT | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Zylberberg, B | 1 |
| Dormont, D | 1 |
| Madelenat, P | 1 |
| Daraï, E | 1 |
| Samel, S | 1 |
| Löhr, M | 1 |
| Mishra, A | 1 |
| El-Naggar, AK | 1 |
| DeMonte, F | 1 |
| Hanna, EY | 1 |
| Saiers, JH | 1 |
| Slavik, M | 1 |
| Joss, RA | 1 |
| Cavalli, F | 1 |
| Goldhirsch, A | 1 |
| Mermillod, B | 1 |
| Brunner, KW | 1 |
| Matthiessen, W | 1 |
| Stempinski, E | 1 |
| Göbel, D | 1 |
| Thalmann, U | 1 |
| Einhorn, LH | 1 |
| Roth, BJ | 1 |
| Ansari, R | 1 |
| Dreicer, R | 1 |
| Gonin, R | 1 |
| Loehrer, PJ | 2 |
| Motzer, RJ | 1 |
| Rodriguez, E | 1 |
| Reuter, VE | 1 |
| Bosl, GJ | 1 |
| Mazumdar, M | 1 |
| Chaganti, RS | 1 |
| Leo, AD | 1 |
| Biganzoli, L | 1 |
| Bohm, S | 1 |
| Lupi, G | 1 |
| Oriana, S | 1 |
| Riboldi, G | 1 |
| Spatti, G | 1 |
| Vicario, G | 1 |
| Di Re, F | 1 |
| Bajetta, E | 1 |
| Conte, PF | 1 |
| Gadducci, A | 1 |
| Fioretti, P | 1 |
| Bruzzone, M | 1 |
| Brunetti, I | 1 |
| Ragni, N | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Hutson, E | 1 |
| Sutton, G | 1 |
| Pierga, JY | 1 |
| Kalifa, C | 1 |
| Terrier-Lacombe, MJ | 1 |
| Habrand, JL | 1 |
| Lemerle, J | 1 |
| Lim, JT | 1 |
| Green, JA | 1 |
| Lorusso, V | 2 |
| Catino, A | 2 |
| Leone, B | 3 |
| Rabinovich, M | 2 |
| Gargano, G | 2 |
| Paradiso, A | 1 |
| De Lena, M | 2 |
| Perez, JE | 1 |
| Machiavelli, M | 3 |
| Leone, BA | 1 |
| Romero, A | 2 |
| Rabinovich, MG | 1 |
| Vallejo, CT | 1 |
| Bianco, A | 1 |
| Lacava, JA | 1 |
| Rodriguez, R | 1 |
| Cuevas, MA | 2 |
| Sutton, GP | 5 |
| Blessing, JA | 5 |
| DiSaia, PJ | 1 |
| McGuire, WP | 1 |
| Heideman, RL | 1 |
| Douglass, EC | 1 |
| Langston, JA | 1 |
| Krischer, JP | 1 |
| Burger, PC | 1 |
| Kovnar, EH | 1 |
| Kun, LE | 1 |
| Friedman, HS | 1 |
| Kadota, R | 1 |
| Vallejo, C | 2 |
| Perez, J | 1 |
| Lacava, J | 1 |
| Focaccia, G | 1 |
| Ferreyra, R | 1 |
| Suttora, G | 1 |
| Castaldi, J | 1 |
| Arroyo, A | 1 |
| Lotz, JP | 1 |
| Bouleuc, C | 1 |
| André, T | 1 |
| Touboul, E | 1 |
| Macovei, C | 1 |
| Hannoun, L | 1 |
| Lefranc, JP | 1 |
| Houry, S | 1 |
| Uzan, S | 1 |
| Izrael, V | 1 |
| Perkins, JB | 1 |
| Effenbein, GJ | 1 |
| Fields, KK | 1 |
| Thigpen, T | 2 |
| Vance, R | 1 |
| Khansur, T | 1 |
| Malamud, F | 1 |
| Stein, ME | 2 |
| Ruff, P | 1 |
| Weaving, A | 1 |
| Fried, J | 1 |
| Bezwoda, WR | 1 |
| Erkisi, M | 1 |
| Erkurt, E | 1 |
| Ozbarlas, S | 1 |
| Burgut, R | 1 |
| Doran, F | 1 |
| Seyrek, E | 1 |
| Teicher, BA | 1 |
| Holden, SA | 1 |
| Goff, DA | 1 |
| Wright, JE | 1 |
| Tretyakov, O | 1 |
| Ayash, LJ | 1 |
| Weiss, AJ | 1 |
| Lackman, RD | 1 |
| Kaijser, GP | 1 |
| Beijnen, JH | 1 |
| Bult, A | 1 |
| Keizer, HJ | 1 |
| Underberg, WJ | 1 |
| Drumea, K | 1 |
| Veyhl, M | 1 |
| Wagner, K | 1 |
| Volk, C | 1 |
| Gorboulev, V | 1 |
| Baumgarten, K | 1 |
| Weber, WM | 1 |
| Schaper, M | 1 |
| Bertram, B | 1 |
| Wiessler, M | 1 |
| Koepsell, H | 1 |
| Di Vagno, G | 1 |
| Manzione, L | 1 |
| Palmeri, S | 1 |
| Nacci, G | 1 |
| Bilancia, D | 1 |
| Leonardi, V | 1 |
| Loverro, G | 1 |
| Selvaggi, L | 1 |
| Topuz, E | 1 |
| Saip, P | 1 |
| Aydmer, A | 1 |
| Salihoğlu, Y | 1 |
| Berkman, S | 1 |
| Bengisu, E | 1 |
| Aziz, Z | 1 |
| Zahid, M | 1 |
| Ud Din Ahmed, Z | 1 |
| Arshad, T | 1 |
| Steyn, RS | 1 |
| Darnton, SJ | 1 |
| McManus, KG | 1 |
| McAleer, JA | 1 |
| Cullen, MH | 1 |
| Matthews, HR | 1 |
| Roques, B | 1 |
| Pichon, A | 1 |
| De Laroche, G | 1 |
| Garnier, JF | 1 |
| Jacquin, JP | 1 |
| Donato, ML | 1 |
| Gershenson, D | 1 |
| Ippoliti, C | 1 |
| Wharton, JT | 1 |
| Bast, RC | 1 |
| Aleman, A | 1 |
| Anderlini, P | 1 |
| Gajewski, JG | 1 |
| Giralt, S | 1 |
| Molldrem, J | 1 |
| Ueno, N | 1 |
| Lauppe, J | 1 |
| Korbling, M | 1 |
| Boyer, J | 1 |
| Bodurka-Bevers, D | 1 |
| Bevers, M | 1 |
| Burke, T | 1 |
| Freedman, R | 1 |
| Levenback, C | 1 |
| Wolf, J | 1 |
| Champlin, RE | 1 |
| Wick, MR | 1 |
| Günzburg, WH | 1 |
| Salmons, B | 1 |
| Ritter, S | 1 |
| Schröder, HJ | 1 |
| Kokron, O | 1 |
| Titscher, R | 1 |
| Micksche, M | 1 |
| Cerni, C | 1 |
| Wrba, H | 1 |
| Mitrou, PS | 1 |
| Fischer, M | 1 |
| Mitrou, G | 1 |
| Röttger, P | 1 |
| Buxton, EJ | 1 |
| Lambuth, BW | 1 |
| Vance, RB | 1 |
| Manetta, A | 1 |
| Homesley, H | 1 |
| McGuire, W | 1 |
| Markman, M | 1 |
| Hakes, T | 1 |
| Reichman, B | 1 |
| Lewis, JL | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Almadrones, L | 1 |
| Pizzuto, F | 1 |
| Hoskins, W | 1 |
| Kredentser, DC | 1 |
| Buesa, JM | 1 |
| Fernández, R | 1 |
| Esteban, E | 1 |
| Estrada, E | 1 |
| Barón, FJ | 1 |
| Palacio, I | 1 |
| Gracia, M | 1 |
| Lacave, AJ | 1 |
| Photopulos, G | 2 |
| Berman, ML | 3 |
| Homesley, HD | 3 |
| Tropé, C | 1 |
| Kaern, J | 1 |
| Vergote, I | 1 |
| Vossli, S | 1 |
| Willemse, PH | 1 |
| de Jong, PE | 1 |
| Elema, JD | 1 |
| Mulder, NH | 1 |
| Malfetano, J | 1 |
| Peake, MD | 1 |
| Parker, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and IL2 for Treatment of Advanced Solid Tumors[NCT04770207] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
| Phase I Trial of High-dose Topotecan in Association With Carboplatin, With Peripheral Blood Stem Cell Support in Patients With First Relapsed Ovarian Carcinoma Without Platinum-treatment Since 6-12 Months[NCT01177501] | Phase 1 | 3 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to choice of the principal investigator) | ||
| Conventional Dose Chemotherapy for Ovarian Cancer Supported by Autologous Haematopoietic Stem Cell Transfusion[NCT05401162] | 40 participants (Anticipated) | Interventional | 2022-04-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for ifosfamide and Carcinoma
| Article | Year |
|---|---|
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell- and Tissue-Based Therapy; Chemoembolization, Therap | 2013 |
Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diplopia; Doxorubicin; | 2016 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch | 2009 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; | 2012 |
Ifosfamide in the treatment of malignant epithelial ovarian tumors.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Female; Humans; Ifosfamide; Ovarian Neoplasms; Sarcoma | 2003 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Ifosfamide and mesna in epithelial ovarian carcinoma.
Topics: Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; | 1993 |
Carcinoma of the choroid plexus: a pediatric experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Chil | 1993 |
The role of ifosfamide and systemic therapy in the management of carcinoma of the cervix.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 1996 |
Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Doxorubicin; Dr | 1997 |
Thymic malignancies.
Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antineoplastic Agents; Antineoplastic Combined Chemothe | 2001 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Canc | 2001 |
The role of ifosfamide in gynecologic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Genital Neoplasms, Female; Humans | 1992 |
Gynecologic Oncology Group studies with ifosfamide.
Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita | 1992 |
27 trials available for ifosfamide and Carcinoma
| Article | Year |
|---|---|
Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2003 |
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2003 |
A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp | 2004 |
First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Ca | 2004 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Anti | 1984 |
Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cal | 1994 |
An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Fema | 1994 |
Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cobalt | 1994 |
Ifosfamide and mitoxantrone as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Drug Admin | 1993 |
Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Female; Humans; Ifosfamide; Mesna; Middle Aged; Uterine Cerv | 1993 |
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Child | 1995 |
Ifosfamide and cisplatin as neoadjuvant chemotherapy for advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1996 |
Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Car | 1996 |
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylatin | 1996 |
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1996 |
The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas | 1996 |
Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carb | 1998 |
Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Feasibility Studi | 1998 |
Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A | 1998 |
A phase II trial of four courses of preoperative chemotherapy in squamous or anaplastic carcinoma of the oesophagus.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Al | 1998 |
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carcinoma; Combined | 2000 |
[Clinical experience with the cytostatic drug ifosfamide].
Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther | 1977 |
[Clinical experiences with Holoxan in small cell carcinoma of the bronchus (author's transl)].
Topics: Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Male; Neoplasm Metastasis; Qua | 1977 |
Experience with bleomycin, ifosfamide, and cisplatin in primary and recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1992 |
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosf | 1992 |
Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Evaluation; Head and Ne | 1991 |
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
Topics: Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Leukocyte Count; Mercaptoethanol; Mesna; Mul | 1989 |
31 other studies available for ifosfamide and Carcinoma
| Article | Year |
|---|---|
Complete Response Induced by Concurrent Chemoradiotherapy in a Patient with NUT Carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Hum | 2022 |
NUT Carcinoma in Children and Adolescents: The Expert European Standard Clinical Practice Harmonized Recommendations.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Child; Cisplatin; Cyclophosph | 2023 |
Pediatric nasal NK/T-cell lymphoma microscopically mimicking carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemorad | 2020 |
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Etoposide; Hu | 2020 |
Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Carboplatin; Carcinoma; Chemot | 2015 |
First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Doxorub | 2016 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytid | 2015 |
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human | 2016 |
Tender nodules on the palms and soles after chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Drug-Related Side Effects and Adverse Reactions; Epiru | 2008 |
Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Topics: Animals; Antineoplastic Agents; Carcinoma; Chromatography, High Pressure Liquid; Cytochrome P-450 En | 2002 |
Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Carcinoma; Cell Line, Tumor; Ce | 2007 |
Endodermal sinus tumor of the paranasal sinuses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Endodermal Sinus Tumor; Humans | 2008 |
Pilot study of intravenous ifosfamide plus oral acetylcysteine in the treatment of non-small cell lung cancer.
Topics: Acetylcysteine; Adenocarcinoma; Administration, Oral; Carcinoma; Carcinoma, Small Cell; Carcinoma, S | 1981 |
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos | 1983 |
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma | 1995 |
Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Evaluation | 1994 |
Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A | 1993 |
Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Female; Humans; | 1993 |
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 1996 |
Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.
Topics: Adult; Antineoplastic Agents, Alkylating; Carcinoma; Chromatography, Gas; Cyclophosphamide; Humans; | 1997 |
Ifosfamide/cisplatin-based chemotherapy in metastatic undifferentiated nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; | 1997 |
Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carcinoma; Glucose; Humans; Ifosfa | 1998 |
[Intra-abdominal desmoplastic small round-cell tumors. An entity among peritoneal carcinomatoses in young adults].
Topics: Abdominal Neoplasms; Abdominal Pain; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protoco | 2000 |
The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB x NZW) mice. II. Emergence of tumors in young animals treated with azathioprine and ifosfamide, including a histologic assessment of the neoplasms.
Topics: Animals; Azathioprine; Carcinogens; Carcinoma; Cyclophosphamide; Female; Hyperplasia; Ifosfamide; Ly | 1979 |
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female | 1991 |
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies.
Topics: Antineoplastic Agents; Carcinoma; Drug Evaluation; Female; Humans; Ifosfamide; Mercaptoethanol; Mesn | 1990 |
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Evaluation; | 1990 |
Severe renal failure following high-dose ifosfamide and mesna.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma; Dose-Respons | 1989 |
Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
Topics: Adult; Aged; Carcinoma; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; Male; Mesna; Nervous | 1989 |
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci | 1989 |
Ifosfamide as single-agent chemotherapy in inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1985 |